Gene Therapy Saves 4-Year-Old with Rare Immune Disorder Once Considered Fatal

Published on Spencer Knight via LinkedIn

Eisa Hussain was diagnosed as an infant with leukocyte adhesion deficiency type 1 (LAD-1), a rare and deadly immune disorder. Without treatment, children with LAD-1 typically don’t survive past age two. Thanks to a gene therapy developed by Rocket Pharmaceuticals and delivered at Great Ormond Street Hospital, Eisa’s own stem cells were genetically corrected to restore immune function.

Now, months later, Eisa is thriving—playing football, attending school, and living the kind of life his family never thought possible. Spencer Knight calls it a life-changing breakthrough and a symbol of hope for families affected by rare immune disorders.

Read the full article via The Times (UK):

👉 Gene therapy trial saves boy, 4, from ‘death sentence’

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.